新诊断多发性骨髓瘤18F-FDG PET/CT代谢异质性的预后影响
该回顾性研究纳入203例新诊断多发性骨髓瘤患者,用18F-FDG PET/CT的累积SUV体积直方图曲线下面积评估代谢异质性(MH)。以SUVmax最高病灶计算的MH-SUVmax较高组无进展生存期和总生存期显著更短,且多因素分析中保持独立预后价值。高MH-SUVmax合并高危细胞遗传学异常者即使接受标准治疗预后仍差。
要点
- 以SUVmax最高病灶评估的MH比最大MTV病灶的MH更具预后相关性。
- 高MH-SUVmax组中位PFS 25.2 vs 33.9个月,中位OS 41.6 vs 112.0个月。
- 高MH-SUVmax合并高危细胞遗传学异常者中位PFS 10.0个月、OS 33.3个月。
核心结论
- 基于治疗前18F-FDG PET/CT的MH-SUVmax高表达是新诊断多发性骨髓瘤的独立预后不良因素。
研究设计与样本
- 回顾性分析203例新诊断多发性骨髓瘤患者,采用18F-FDG PET/CT的累积SUV体积直方图曲线下面积评估代谢异质性。
- 分别选取SUVmax最高病灶(MH-SUVmax)和MTV最大病灶(MH-MTV)两种方式评估MH。
主要发现
- MH-SUVmax病灶的代谢异质性比MTV最大病灶的代谢异质性更具预后相关性。
- 高MH-SUVmax组较低MH-SUVmax组中位PFS显著更短(25.2 vs 33.9个月,P=0.004)。
- 高MH-SUVmax组较低MH-SUVmax组中位OS显著更短(41.6 vs 112.0个月,P=0.046)。
- 多因素分析显示高MH-SUVmax保持独立预后价值。
- 全身MTV高的患者中,高MH-SUVmax者预后趋于更差(中位PFS 23.8 vs 30.2个月,P=0.085)。
关键数值与推荐
- 代谢异质性以累积SUV体积直方图曲线下面积评估。
- MH评估分别选取SUVmax最高病灶和MTV最大病灶。
临床怎么用
- 治疗前18F-FDG PET/CT可基于SUVmax最高病灶评估MH-SUVmax,辅助识别预后不良的多发性骨髓瘤患者。
- 高MH-SUVmax合并高危细胞遗传学异常提示标准治疗预后差,可供临床风险分层参考。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study aimed to investigate the prognostic impact of metabolic heterogeneity (MH) in patients with multiple myeloma (MM). PATIENTS AND METHODS: We retrospectively analyzed MH with 18F-FDG PET/CT in 203 patients with newly diagnosed MM. Metabolic heterogeneity was estimated using the area under the curve of the cumulative SUV volume histogram. To evaluate MH, we selected 2 lesions: "MH-SUVmax," a lesion with SUVmax, and "MH-metabolic tumor volume (MTV)," a lesion with the largest MTV. RESULTS: Metabolic heterogeneity from an MH-SUVmax lesion showed more prognostic relevance than that from a lesion with the largest MTV. The progression-free survival (PFS) and overall survival (OS) rates were significantly lower in the high-MH-SUVmax group than in the low-MH-SUVmax group (median PFS: 25.2 vs 33.9 months; median OS: 41.6 vs 112.0 months; P = 0.004 and 0.046, respectively), whereas high MH-SUVmax retained independent prognostic power on multivariate analysis. Even among patients with high whole-body MTV, those with high MH-SUVmax tended to show poorer prognosis than those without (median PFS, 23.8 vs 30.2 months; P = 0.085). Moreover, patients with high MH-SUVmax and high-risk cytogenetic abnormalities showed dismal outcomes even with standard treatment (median PFS and OS, 10.0 and 33.3 months, respectively). CONCLUSIONS: Our results suggested that high MH-SUVmax based on pretreatment with 18F-FDG PET/CT is a novel prognostic factor for cases of MM.
引用
- Terao T, Machida Y, Hirata K, et al. Prognostic Impact of Metabolic Heterogeneity in Patients With Newly Diagnosed Multiple Myeloma Using 18F-FDG PET/CT. Clin Nucl Med. 2021. PMID: 34172600. doi:10.1097/RLU.0000000000003773
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。